Joel Jean

Joël oversees all operations at Ysios Capital, including management, strategy and standard operations. Joël serves on the board of TiGenix, AM-Pharma, MedLumics, and is chairman of the board at Inbiomotion. Formerly, he was board observer at Biovex (now AMGEN) and chairman of the board at Cellerix (now TiGenix). Previously, Joël co-founded GLYCART Biotechnology AG (Zürich, Switzerland) in March 2001 and was Chief Executive since inception. He raised €15 million in three rounds of financing for GLYCART before the company was sold to F.Hoffmann-La Roche Ltd in July 2005, a deal lauded as the deal of the year by the European Venture Capital magazine. As Chief Executive, he led all the fund-raising efforts, established a pan-European investment syndicate with leading venture capital firms and structured, negotiated and executed several key in- and out-licensing agreements with global pharmaceutical and biotechnology companies. Joël holds a master’s degree in Biochemistry, with a specialization in Biotechnology, and a PhD in the fields of cell biology and immunotherapeutics, both from the Swiss Federal Institute of Technology (ETH) in Zürich. He was elected one of the 50 key players in biotechnology in Switzerland in 2003 and earned several innovation awards for GLYCART, including the Wall Street Journal Europe Innovation Award in 2001.